# EDGAR Filing Document

**Accession Number:** 0000310158
**File Stem:** 0001193125-26-147718
**Filing Date:** 2026-4
**Character Count:** 4881
**Document Hash:** be0620abf199dcf15d62b3b632cf81b4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-147718.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001193125-26-147718

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260408

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merck & Co., Inc.
- **CENTRAL INDEX KEY:** 0000310158
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 221918501
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-06571
- **FILM NUMBER:** 26848420

**BUSINESS ADDRESS:**
- **STREET 1:** 126 EAST LINCOLN AVENUE
- **STREET 2:** P.O. BOX 2000
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065
- **BUSINESS PHONE:** 908-740-4000

**MAIL ADDRESS:**
- **STREET 1:** 126 EAST LINCOLN AVENUE
- **STREET 2:** P.O. BOX 2000
- **CITY:** RAHWAY
- **STATE:** NJ
- **ZIP:** 07065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Merck & Co. Inc.
- **DATE OF NAME CHANGE:** 20091103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SCHERING PLOUGH CORP
- **DATE OF NAME CHANGE:** 19920703

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14A** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to Section 240.14a-12

![LOGO](g74784g00s01.jpg)

**Merck & Co., Inc.** 

**(Name of Registrant as Specified In Its Charter)** 

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** 

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

![LOGO](g74784dsp001.jpg)

Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V90969-P46756-Z92129 \*Please check the meeting materials for any special requirements for meeting attendance. MERCK & CO., INC. 126 EAST LINCOLN AVENUE RAHWAY, NJ 07065 MERCK & CO., INC. 2026 Annual Meeting Vote by May 25, 2026 11:59 PM ET You invested in MERCK & CO., INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 26, 2026. Vote Virtually at the Meeting\* May 26, 2026 9:00 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/MRK2026 Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 12, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639, or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Merck

------

![LOGO](g74784dsp002.jpg)

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". Voting Items Board Recommends V90970-P46756-Z92129 1. Election of Directors Nominees: 1a. Douglas M. Baker, Jr. For 1b. Mary Ellen Coe For 1c. Pamela J. Craig For 1d. Robert M. Davis For 1e. Thomas H. Glocer For 1f. Surendralal L. Karsanbhai For 1g. Risa J. Lavizzo-Mourey, M.D. For 1h. Stephen L. Mayo, Ph.D. For 1i. Paul B. Rothman, M.D. For 1j. Patricia F. Russo For 1k. Christine E. Seidman, M.D. For 1l. Inge G. Thulin For 1m. Kathy J. Warden For 2. Non-binding advisory vote to approve the compensation of our named executive officers. For 3. Ratification of the appointment of the Company's independent registered public accounting firm for 2026. For 4. Shareholder proposal regarding a report on DEI risks in federal contracting. Against 5. Shareholder proposal regarding a report on healthcare coverage gaps. Against 6. Shareholder proposal regarding a report on political contributions. Against THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.